Navigation Links
SQI Diagnostics Contracted to Automate Pathogen Detection Assays

TORONTO, Aug. 22, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that it has entered into a Master Service Agreement to contract with a UK-based company to automate their DNA-based pathogen detection assays. During the initial phase of this agreement, SQI will be paid to deliver an automated working prototype of one of the customer's assays, operational on SQI's sqidlite™ system. The initial phase is scheduled for completion by mid-September 2014. It is anticipated that other molecular diagnostic tests will be commissioned in a separate agreement following successful implementation of the initial phase.

The first assay being automated is used to identify pathogens in raw milk from dairy cows. Currently, dairy cows are routinely tested for health through a global network of laboratories and when symptoms of bacterial infections appear, pathogens are commonly detected using traditional plate cultures.  The new application can be used for much faster and more accurate identification of multiple pathogens simultaneously. The UK-based company is developing additional assays for agriculture, food safety and human pathogen testing, intended to screen high volumes of samples on a regular basis.

"As we've explored this opportunity, we've been impressed by the compatibility and synergy of our new customer's high-performance molecular diagnostic technology with our automated multiplexing assay technologies," said Andrew Morris, CEO of SQI Diagnostics. "Although our automated systems have been developed to run our own protein-based IVD and pharma assays, our technology solution is highly adaptable to other types of tests and this presents a valuable additional market opportunity where our technologies can be applied with the potential for significant test volumes and revenue."

About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company's proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit

Forward-looking Information
This news release contains certain forward-looking statements, including, without limitation, statements containing the words "will", "expects", "intends" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to risks related to the failure to obtain necessary regulatory approvals, general economic and market segment conditions, and international risk and currency exchange, agreements and future agreements to sell our products, the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business, the successful regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic kits, the acceleration of our revenue ramp, general economic and market segment conditions, competitor activity, technology changes and regulatory approvals. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company's ongoing filings with the securities regulatory authorities, which filings can be found at Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE SQI Diagnostics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics Declares Quarterly Cash Dividend
2. PDI, Inc. Subsidiary Interpace Diagnostics Enters Molecular Diagnostics Market with Thyroid and Pancreatic Cancer Test Portfolio Acquisition
3. Advanced Cell Diagnostics and Leica Biosystems Begin Co-marketing Fully Automated RNA in situ Hybridization Assay
4. Companion Diagnostics in Personalized Medicine and Cancer Therapy
5. Point of Care Diagnostics, BCC Research
6. MGC Diagnostics Corporation Completes Acquisition of MediSoft SA
7. Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine
8. Quest Diagnostics Reports Second Quarter 2014 Financial Results
9. Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare
10. Daktari Accepted into WHO Prequalification of Diagnostics Programme
11. Beckman Coulter to Acquire Siemens Healthcare Diagnostics Clinical Microbiology Business
Post Your Comments:
(Date:10/13/2015)... Ga. , Oct. 13, 2015  EndoChoice Holdings, ... its third quarter 2015 financial results on Thursday, November ... . --> . ... on Thursday, November 5, 2015 at 9:00 a.m. ET ... 328-5344 for domestic callers and (412) 317-5469 for international ...
(Date:10/13/2015)... --> --> ... from the Asthma and COPD Therapies market? Which areas are ... brand new report shows you potential revenues to 2025, assessing ... provides 260 tables, charts, and graphs. Discover the most lucrative ... new study lets you assess forecasted sales at overall world ...
(Date:10/13/2015)... 13, 2015  XiMo AG ( Lucerne ... Inc. ( Milpitas, California ) announced today ... chemistry. The importance of metathesis chemistry was highlighted by ... of this application. This industrially-relevant application has been utilized ... pharmaceuticals, specialty chemicals, and polymers. Georg Fráter ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... PhyMed Healthcare ... today announced its partnership with WPC Healthcare , a provider of predictive ... organizes the data into an aggregated data repository necessary to perform reporting and ...
(Date:10/13/2015)... ... 13, 2015 , ... Altec Products, Inc., the leader in ... Dynamics AXUG, GPUG and NAVUG Summits to take place the week of October ... user conferences designed and led by users to provide attendees with a unique ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... through a unique private messaging application, announced today a significant contract that will ... five years. Independence plans to build on the growing success of its Relay ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... A child ... that’s why SmileCareClub , the leading remote invisible aligner system, has joined with ... would otherwise go without it. For each aligner treatment plan purchased, SmileCareClub will donate ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... product that targets the unique health needs of new moms. Postnatal Omega-3, ... Association ( ), utilizes Nordic Naturals’ exclusive, new, ultra-concentrated omega-3 oil. ...
Breaking Medicine News(10 mins):